title: Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
abstract: Potential drugdrug interactions are a concern for patients taking tamoxifen.
  
  
  
  This study was designed to determine the effect of coadministering desvenlafaxine on tamoxifen pharmacokinetics.
  
  
  
  This open-label, 2-period inpatient and outpatient study enrolled healthy, postmenopausal women. Period 1, day 1, subjects were administered tamoxifen 40 mg followed by 23 days of blood sampling for pharmacokinetic analyses. During period 2, subjects received desvenlafaxine 100 mg/d for 28 days; a single dose of tamoxifen 40 mg was administered with desvenlafaxine 100 mg on day 7, followed by 23 days of blood sampling. Pharmacokinetics of tamoxifen and its metabolites (AUC over infinite time (AUC(inf)), AUC to the last measurable concentration (AUC(last)), peak plasma concentration (C(max)) were compared for monotherapy vs. combination therapy using the ratio of adjusted mean differences. A superposition method was used in the statistical analysis of N-desmethyl-tamoxifen and endoxifen to address the carry-over observed for those metabolites. The test for interaction was considered negative if the 90% confidence intervals (CIs) for the ratios were within 80 - 125%.
  
  
  
  Coadministration of tamoxifen with steady-state desvenlafaxine did not alter tamoxifen AUC(inf), AUC(last), and C(max), as reflected by the ratio of adjusted geometric means (90% CIs) of 100.7% (96.7%, 104.9%), 103.5% (100.2%, 106.9%), and 99.4% (94.0%, 105.2%), respectively. Similarly, coadministration did not alter 4-hydroxy- tamoxifen and N-desmethyl-amoxifen pharmacokinetics. The 11.8% (88.2% (82.6%, 94.2%)) and 8.0% (92.0% (84.7%, 100.0%)) decreases in endoxifen AUC(last) and C(max), respectively, were not significant (90% CIs fell wholly within the prespecified acceptance range).
  
  
  
  Steady-state desvenlafaxine 100 mg did not affect tamoxifen pharmacokinetics. For women treated with tamoxifen, desvenlafaxine may represent a safe and effective treatment unlikely to alter tamoxifen efficacy.
authors.forename: Alice I
authors.initials: AI
authors.lastname: Nichols
authors.forename: Shannon
authors.initials: S
authors.lastname: Lubaczewski
authors.forename: Yali
authors.initials: Y
authors.lastname: Liang
authors.forename: Kyle
authors.initials: K
authors.lastname: Matschke
authors.forename: Gabriel
authors.initials: G
authors.lastname: Braley
authors.forename: Tanya
authors.initials: T
authors.lastname: Ramey
mesh_terms: D019540:Area Under Curve; D000069468:Desvenlafaxine Succinate / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D013629:Tamoxifen / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*
chemical_list: D013629:Tamoxifen; C016601:afimoxifene; C028787:N-desmethyltamoxifen; D000069468:Desvenlafaxine Succinate